Sansure Biotech Inc.SSE: 688289

Announcement on Convening the Q3 2025 Performance Briefing

Nov 26, 2025 · Issued by Sansure Biotech Inc. via Shanghai Stock Exchange

Filed with SSE · Nov 26, 2025

On 6ix: 6ix.com/news/announcement-on-convening-the-q3-2025-performance-briefing-979

Announcement on Convening the Q3 2025 Performance Briefing

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Sansure Biotech Inc. on 6ix

Earlier from Sansure Biotech

Announcement on Resolutions of the 4th Extraordinary General Meeting in 2025Nov 18, 2025
Announcement on Voluntary Disclosure in the Related Product Obtaining the Medical Device Registration Certificate and the EU CE CertificationNov 8, 2025
Announcement on Resignation of Core Technical PersonnelOct 31, 2025
Announcement on Establishing a Fund through Co-investment with Professional Institutions and Related Party TransactionOct 22, 2025
Announcement on Implementation of Semi-annual Dividend Distribution for 2025Sep 17, 2025

Later from Sansure Biotech

Announcement on Resolutions of the 5th Extraordinary Meeting of the 3rd Board of Directors in 2025Nov 29, 2025
Indicative Announcement on Proposed Judicial Freezing and Enforcement of Some Shares Held by Shareholder with Over 5% SharesDec 6, 2025
Announcement on Voluntary Disclosure in the Related Product Obtaining the EU CE CertificationDec 12, 2025
Announcement on Vesting Results for the 1st Vesting Period of the Initial Granted Part under the 2023 Phase II Restricted Stock Incentive PlanDec 20, 2025
Announcement on Voluntary Disclosure of Clinical Trial Approval for New Indications of a Product of a Holding SubsidiaryFeb 27

All Sansure Biotech news releases

Follow Sansure Biotech into a list and get an email when it puts out news.

Follow Sansure Biotech